The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 58 | — | 20.1x | Near average | |
Growth | 31 | — | 5.6% | Below average | |
Quality | 17 | -44.6% | 7.6% | Below average | |
Safety | 74 | 0.4x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Apogee Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Apogee Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The average price target for Apogee stock saw a slight decline of 1.85% over the past week to reach $109.73, despite the number of analysts remaining stable at 5. This adjustment reflects a state of limited caution in short-term expectations, especially with a wide gap (Dispersion) between the highest price target ($140) and the lowest ($81), indicating a variance in estimating the growth speed of the company's drug portfolio.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.